Cargando…
55. A case for continuing tocilizumab beyond 12 months in giant cell arteritis?
INTRODUCTION: This case discusses a 60-year-old old gentleman who had aggressive disease and severe complications of giant cell arteritis. Shortly after diagnosis of GCA, he had an aortic dissection which was successfully repaired surgically. Medical therapy was escalated by increasing steroids and...
Autores principales: | Ming, Caroline, Stack, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761421/ http://dx.doi.org/10.1093/rap/rkz028.024 |
Ejemplares similares
-
Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013) -
Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022) -
49. Giant cell arteritis and Takayasu arteritis: two sides of the same coin in an elderly female?
por: Ghuman, Hira, et al.
Publicado: (2019) -
Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022) -
Profile of tocilizumab and its potential in the treatment of giant cell arteritis
por: Mollan, Susan Patricia, et al.
Publicado: (2018)